

## Oral Communications

ID	Title	Presenting Author
<b>22/05/2025</b>	<b>11.10 - 12.10</b>	<b>The statins breakthrough in HIV management</b>
<b>37</b>	Achievement of Low-Density Lipoprotein (LDL-C) Targets Based on Individual Cardiovascular Risk in a Cohort of People with HIV (PWH): One-Year Follow-Up Assessment	Beatrice Caloni, Milano
<b>244</b>	Statin prescription, acceptability and tolerability in a cohort of people living with HIV (PLWH) after updated recommendations on statin therapy.	Alessandra Bailoni, Siena
<b>176</b>	Impact of REPRIEVE indications on statin prescription in people with HIV in a real-life setting	Rebecka Papaioannu Borjesson, Milano
<b>338</b>	Statins reduce frailty in people with HIV	Jovana Milic, Modena
<b>22/05/2025</b>	<b>12.15 - 13.15</b>	<b>The evolving tale of HIV: shifting patterns, emerging HIV care</b>
<b>255</b>	Progresses in the continuum of care of people living with HIV, using surveillance and cohort data. Italy, 2012-2023	Assunta Navarra, Roma
<b>260</b>	Disaggregated data on testing activity for HIV in the context of community based voluntary counselling and testing services in the last years in Italy (2019-2023): towards a national registry	Pierluca Piselli, Roma
<b>5</b>	Expanding HIV Screening Beyond Hospital Walls in Milan: 17 years of the "EasyTest" project	Angelo Roberto Raccagni, Milano
<b>261</b>	Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?	Annalisa Mondì, Roma
<b>22/05/2025</b>	<b>14.05 - 15.05</b>	<b>Long acting PrEP in clinical practice</b>
<b>167</b>	Preliminary insights into the pharmacokinetics of long-acting Cabotegravir for PrEP: differential blood and seminal fluid concentrations analysis	Eleonora Sabetta, Milano
<b>209</b>	Preliminary Results of Long-Acting Injectable PrEP with Cabotegravir at San Raffaele Institute in Milan	Angelo Roberto Raccagni, Milano
<b>78</b>	Determinants for the start of long-acting injectable cabotegravir as pre-exposure prophylaxis: a case-control analysis	Roberto Rossotti, Milano
<b>292</b>	Real-world implementation of long-acting PrEP with injectable cabotegravir: preliminary data from an Italian cohort	Valentina Mazzotta, Roma
<b>22/05/2025</b>	<b>14.30 - 15.55</b>	<b>Defining immune correlates in the context of ART and vaccination</b>
<b>262</b>	The impact of long-acting injectable cabotegravir plus rilpivirine in PWH on macrophage/monocyte activation and neuronal injury	Maria Antonella Zingaropoli, Roma
<b>221</b>	Changes in CD8+ T-cell activation after switching from suppressive 3-drug to 2-drug cART in people with HIV	Diego Ripamonti, Bergamo
<b>150</b>	Impact of long-acting therapy and CMV-coinfection on immune activation and senescence in People with HIV(PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine	Mariasilvia Guardiani, Roma
<b>7</b>	Long-lasting immunity: smallpox-specific T Cells show distinct memory traits compared to SARS-CoV-2 T Cells	Sara De Biasi, Modena
<b>95</b>	Two-year neutralizing and T-cell response after MVA-BN vaccination according to HIV infection and CD4 cell count	Valentina Mazzotta, Roma
<b>31</b>	Assessment of the specific cellular immune response to the recombinant herpes zoster vaccine in people living with HIV	Grazia Alessio, Roma

## Oral Communications

ID	Title	Presenting Author
<b>22/05/2025</b>	<b>15.10 - 16.10</b>	<b>Optimizing HIV infection management in Italian clinical practice</b>
<b>132</b>	Effectiveness of switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from NNRTI-based ART in virologically suppressed HIV-patients: a retrospective analysis (DRIVE-SWITCH Study).	Roberta Gagliardini, Roma
<b>335</b>	Switching to BICTegravir in ELderly people living with HIV-1 under virologic control: week 144 results from the BICTEL cohort	Riccardo Donà, Roma
<b>116</b>	Effectiveness and safety of switching to BIC/FTC/TAF in second, third and later lines of therapy in virologically suppressed people living with HIV (PWH) on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL STUDY)	Maria Vittoria Cossu, Milano
<b>22/05/2025</b>	<b>16.15 - 17.30</b>	<b>From virus variability to disease and treatment</b>
<b>59</b>	Evaluation of genetic variability and resistance profile in highly treatment-experienced people with HIV-1 with multi-drug resistance enrolled in the PRESTIGIO Registry treated with lenacapavir	Daniele Spalletta, Roma
<b>60</b>	Evaluation of the viral reservoir in virologically suppressed people with HIV treated with LA Cabotegravir + Rilpivirine regimen	Greta Marchegiani, Roma
<b>157</b>	An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity	Lorenzo Piermatteo, Roma
<b>46</b>	Evaluation of the SARS-CoV-2 virus genetic barrier to Remdesivir and Nirmatrelvir in vitro and in vivo	Ilenia Varasi, Siena
<b>110</b>	Whole Genome Sequencing of Adenovirus genotypes and clinical implications in pediatric patients	Luna Colagrossi, Roma
<b>22/05/2025</b>	<b>16.15 - 17.30</b>	<b>Beyond viral suppression: rethinking quality of life in HIV care</b>
<b>128</b>	Stigma experienced by person with HIV/AIDS in the healthcare settings	Lolita Sasset, Padova
<b>316</b>	Challenges in Measuring Health-Related Quality of Life Among Antiretroviral Therapy Experienced People with HIV	Marianna Menozzi, Modena
<b>85</b>	Poor Treatment Satisfaction and Low Quality of Life in Highly-Treatment Experienced People with HIV PWH: insights from PRESTIGIO Registry	Maria Mazzitelli, Padova
<b>72</b>	Neurocognitive Impairment, Sleep Quality, Depression and Anxiety in People Living with HIV: A Cross-Sectional Study	Ambra Barco, Novara
<b>232</b>	Adherence to electronic monitoring of PROs according with multidimensional biophenotypes (MBP)	Elena Matteini, Roma
<b>23/05/2025</b>	<b>10.05 - 11.05</b>	<b>Durability of long-acting ART</b>
<b>286</b>	Effectiveness and Safety of Long-Acting Cabotegravir and Rilpivirine in Older People with HIV: Insights from the GEPPCO Cohort	Emanuele Foca', Brescia
<b>273</b>	Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCohoLART Study	Gabriele Loi, Milano
<b>84</b>	Durability of long acting cabotegravir and rilpivirine in a multicenter real-life cohort of people with HIV	Maria Mazzitelli, Padova
<b>199</b>	Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study	Camilla Muccini, Milano

## Oral Communications

ID	Title	Presenting Author
<b>23/05/2025</b>	<b>11.10 - 12.10</b>	<b>Building connections across care, prevention and education</b>
<b>51</b>	Anlaids School - Through a positive and inclusive view of Sexuality, our STI prevention training.	Silvia Negri, Roma
<b>229</b>	Proactive testing for sexually transmitted and endemic diseases at an open access clinic for migrants: a one year update	Riccardo Ligresti, Milano
<b>68</b>	NGO role in Continuum of Care (CoC): An opportunity not to be missed	Antonella Camposeragna, Roma
<b>52</b>	Chemsex and MDPV: the experience of a community-based chemsex service with increasingly severe and complex clients	Alessandra Maria Bianchi, Milano
<b>23/05/2025</b>	<b>12.15 - 13.15</b>	<b>Clinical HIV insights</b>
<b>47</b>	Incidence of non-AIDS-related cancers in people with HIV in the period 2000-2023: a single center retrospective study	Giacomo Pozza, Milano
<b>108</b>	Treatment interruptions among PWH on INSTI: virologic failure and other reasons for switching therapy in a real-life cohort	Nicola Squillace, Monza
<b>280</b>	Key predictors of optimal viro-immunological response in primary HIV infection	Annalisa Mondì, Roma
<b>247</b>	Body composition and pharmacokinetics of long-acting antiretroviral therapies in a cohort of people living with HIV	Stefania Arsuffi, Brescia
<b>23/05/2025</b>	<b>12.15 - 13.15</b>	<b>The long-acting ART landscape in Italy</b>
<b>186</b>	Virologic outcomes of long acting cabotegravir and rilpivirine in viraemic and poorly adherent PLWH	Gabriele Cavazza, Milano
<b>279</b>	Switching to Long-Acting CAB/RPV: A Real-World Analysis in People Living with HIV	Ludovica De Martino, Roma
<b>133</b>	Effectiveness and patient reported outcomes (PROs) of long-acting ART with cabotegravir/rilpivirine: the Long-Icona study.	Roberta Gagliardini, Roma
<b>293</b>	Patient-reported outcomes (PROs) as a measure of satisfaction with Long-Acting therapy in PWH	Giulia Del Duca, Roma
<b>23/05/2025</b>	<b>12.15 - 13.15</b>	<b>Advances in viral pathogenesis</b>
<b>179</b>	HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential	Stefano D'Anna, Roma
<b>54</b>	Plasma JCV-DNA changes as prognostic marker in Progressive Multifocal Leukoencephalopathy	Ilaria Mainardi, Milano
<b>12</b>	Baseline viral load impacts the aging process in infants with perinatally acquired HIV enrolled in the EARTH cohort	Maria Raffaella Petrara, Padova
<b>134</b>	Expression of HCMV-encoded miRNAs in co-infected PLWH and relationships with inflammation/immune activation	Elisabetta Lazzari, Roma
<b>23/05/2025</b>	<b>14.00 - 15.00</b>	<b>Long-term effectiveness of oral ART</b>
<b>207</b>	Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study	Antonella d'Arminio Monforte, Milano
<b>65</b>	Observational effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced people with HIV across age groups: 24-month results from the Italian BICSTaR cohort	Diana Canetti, Milano
<b>105</b>	Ten years results on the effectiveness and safety of DTG+3TC as a switch regimen in the ODOACRE cohort	Gianmaria Baldin, Roma
<b>202</b>	Long-term durability of dolutegravir/lamivudine dual regimen in a real-world setting (Dolu3TC study)	Diego Ripamonti, Bergamo

## Oral Communications

ID	Title	Presenting Author
<b>23/05/2025 14.00 - 15.00 Access to prevention in different settings</b>		
<b>114</b>	Rising chemsex trends among PrEP users in Milan: a 2024-2025 study	Chiara Fusetti, Milano
<b>36</b>	TelePrEP: New data on a best practice in HIV prevention	Maria Luisa Cosmaro, Milano
<b>32</b>	Is PrEP knowledge a privilege? The unequal access to PrEP Information for cis and trans women and gender non-conforming individuals at HIV testing sites	Carlotta Del Giudice, Torino
<b>63</b>	Facilitators and Barriers HIV/STI Information and Services Among LGBTQI+ Immigrants in Italy	Yerina Ranjit, Columbia
<b>23/05/2025 14.00 - 15.00 HIV and comorbidities</b>		
<b>126</b>	Long-Term Success of Combined Kidney-Liver Transplantation in People with HIV: Evidence from a Real-World Cohort	Adriana Cervo, Modena
<b>123</b>	HIV-to-HIV Organ Transplantation: A Comparative Analysis of Liver and Kidney Transplant Outcomes in People with HIV Receiving Organs from donors without HIV infection	Adriana Cervo, Modena
<b>161</b>	Tobacco and Alternative Nicotine Product Use Among People With HIV: Should We Be Concerned?	Andrea De Vito, Sassari
<b>230</b>	Hypertriglyceridemia and Gender Differences in the Risk of Major Adverse Cardiovascular Events in People with HIV: A Single Center Retrospective Longitudinal Study	Alessia Siribelli, Milano
<b>23/05/2025 14.00 - 15.00 Diagnosis, prevalence and prevention of STIs</b>		
<b>183</b>	Clinical evaluation of gonococcal-specific culture test for rectal gonorrhea diagnosis	Flavia Passini, Milano
<b>154</b>	Progressive Increase of New Syphilis Diagnoses among MSM with HIV Infection: A 30-Year Report from Rome STI Reference Center	Christof Stingone, Roma
<b>79</b>	High-Risk HPV Other than HPV16 Are Common in Advanced Anal Precancerous Lesions in MSM Living With HIV	Eugenio Nelson Cavallari, Roma
<b>73</b>	The actual need of doxyPEP might not be as large as expected.	Roberto Rossotti, Milano
<b>23/05/2025 15.05 - 16.05 ARV drugs from prevention to treatment</b>		
<b>312</b>	The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry	Tommaso Clemente, Milano
<b>165</b>	Risk of developing low-level viral rebound (LLVR) among people with HIV (PWH) with current HIV-RNA ≤ 50 copies/mL receiving 2DR vs 3DR: a case control study	Alessandra Vergori, Roma
<b>282</b>	Advancing HIV care in pregnancy: trends in virological suppression, mother-to-child transmission and postpartum retention over two decades	Federica Casari, Modena
<b>159</b>	Predictors of linkage to prevention services after HIV Post-Exposure Prophylaxis (PEP): a retrospective analysis from 2019 to 2024	Rozenn Esvan, Roma
<b>23/05/2025 15.05 - 16.05 PrEP issues: adherence and STI</b>		
<b>343</b>	Comparison of users accessing PrEP in hospital-based or community-based settings: first picture from the PrIDE cohort	Valentina Mazzotta, Roma
<b>57</b>	Comparing Self-Reported and Pharmacy-Based Monitoring Adherence rates in individual accessing HIV Pre-Exposure Prophylaxis (PrEP): An 18-Month Retrospective Analysis	Roberto Brunoro, Padova
<b>121</b>	STI occurrence among PrEP users: a six-year follow-up study from the Bergamo centre	Serena Venturelli, Bergamo
<b>83</b>	PrEP and STIs screening policies: one size fits all?	Enrico Schlitzer, Bologna